Viral Vectors & Plasmid DNA Manufacturing Market Size US$ 10.6 BN by 2030

The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to be worth around US$ 10.6 billion by 2030 from valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

Growth Factors

Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.

Full Report is Ready | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38494

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Report Coverage

Vector Type Insights

Targeted delivery, efficient transduction, and controlled gene expression are some of the key factors taken into consideration while manufacturing vectors. Viral vectors are increasingly being employed in the ongoing clinical trials owing to their efficiency in gene delivery. Out of all the viral vectors, adenovirus and retrovirus are most commonly used within research settings across the globe.

Workflow Insights

The growing necessity of vectors to meet the rising demand for robust therapies has pronounced the need for optimization of upstream processing and downstream processing workflows. Virus preparation methods at small-scale involve steps that are difficult to scale-up and are often considered tedious.

Application Insights

Antisense and RNAi, gene therapies are the leading application of viral and plasmid vector in terms of revenue share. Small interfering RNAs (siRNAs) are currently considered significant tools for post-transcriptional gene silencing during a genetic analysis of cells. The presence of pipeline products is expected to boost growth of this segment over the forecast period.

Furthermore, the emergence of retroviral vectors as a viable solution for addressing the low transfection efficiency-related drawbacks of plasmid-based systems is one of the key development in antisense and RNAi production. Growing usage of AAV vectors for delivery of siRNA in mammalian cells is driving revenue in this segment.

Ask here for more details@ https://www.visionresearchreports.com/report/enquiry/38494

End-use Insights

Pharmaceutical and biotechnology companies accounted for the largest share in the viral vectors & plasmid DNA manufacturing market in 2019. This can be attributed to the continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies. The number of biotech companies employing vectors for therapeutics production continues to increase over the period of time.

Disease Insights

Viral vectors are being studied for both preventive and therapeutic applications in cancer. Viral vector-based immunization with anticancer antigens or delivery of toxic or anticancer genes are some key areas or research that have shown steady progress in recent times. Furthermore, recent approvals of lentiviral vector-based CAR-T cell therapies for Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma have attracted considerable attention from key end-users. This has resulted in significant proliferation in the cancer-based pipeline projects on advanced therapies.

Regional Insights

Recent FDA approval of advanced therapies such as Kymriah (tisagenlecleucel) and Yescarta is one of the key factors contributing to the largest revenue share of the U.S. market. These approvals have resulted in an increase in the number of companies operating in this area in U.S. In 2020, an estimated 391 gene therapy companies were operating in the U.S. By September 2019, around 100 more companies including big pharma companies entered the market.

Key Players

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Market Segmentation

By Vector Type Outlook

• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others

By Workflow Outlook

• Upstream Processing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
• Downstream Processing
  • Purification
  • Fill-finish

By Application Outlook

• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

By End-use Outlook

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease Outlook

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

By Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38494

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333